1. Home
  2. IMNM

as 09-11-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Founded: 2006 Country:
United States
United States
Employees: N/A City: BOTHELL
Market Cap: 945.8M IPO Year: 2020
Target Price: $24.75 AVG Volume (30 days): 756.6K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.94 EPS Growth: N/A
52 Week Low/High: $5.15 - $16.73 Next Earning Date: 08-06-2025
Revenue: $12,589,000 Revenue Growth: 16.74%
Revenue Growth (this year): -21.86% Revenue Growth (next year): 154.73%

IMNM Daily Stock ML Predictions

Share on Social Networks: